Conference Analysis: Two FDA-approved tau scans disagree 47% of the time. One is right.

Just analyzed six presentations from the Imaging in Neurodegenerative Diseases conference. The findings completely change how we understand Alzheimer's detection:

The Data

- "Concordance is only 47% between tracers" - Dr. Andreia Rocha on MK-6240 vs Flortaucipir

- "MK is always one step ahead" - detecting tau 20-30 centiloids (3-5 years) earlier

- "Cortical thickness may increase in early stages" - Dr. Ting Qiu's 10-year study showing biphasic pattern

Why This Matters:

1. If you're getting tau PET, the tracer choice determines whether problems are caught

2. Brain enlargement before shrinkage = missed intervention window

3. Pharmaceutical companies have already chosen MK-6240 for trials

The Brain Drainage Discovery:

Dr. James LeFevre (Vanderbilt) presented DOORS tool - 96% accurate at detecting enlarged perivascular spaces (failed brain waste clearance) years before symptoms.

Action Items:

- Ask which tau tracer if getting PET scan

- P-tau217 blood test available ($300-400)

- Standard MRI can show drainage problems

The video covers:

- All six presentations analyzed

- Why scans disagree (different tau conformations)

- Three distinct Alzheimer's patterns

- What this means for early detection

Thoughts on the biphasic brain volume pattern? Anyone else surprised by the scan disagreement rate?

Edit: Industry consultant at conference confirmed pharma companies are using MK-6240 exclusively for trials now.